Nisa Leung 梁颕宇

EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Emulate Inc. is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready Human Emulation System® includes three components: Zoë® Culture Module, Organ-Chips, and analytical software applications. The platform provides a window into the inner workings of human biology and disease—offering researchers a new technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection and have also been awarded Product Design of the Year 2015 by London’s Design Museum.

ChemLex is a Singapore-based company delivering autonomous chemical synthesis services for the pharmaceutical and biotech industry. Our AI-integrated autonomous synthesis platform improves quality, consistency, and productivity while reducing costs and supporting ESG goals.

Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics. ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multi-specific biologics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice. Learn more at www.attovia.com.

【康至德】將前沿研究成果轉化為腦退化症的風險預測、診斷和疾病監測工具，利用血液在症狀出現階段之前檢測出認知障礙症。 At Cognitact, we are translating cutting-edge research efforts into a risk prediction, diagnostic and disease monitoring tool for dementia, aiming to detect Alzheimers disease before its symptomatic stage using blood.

GluBio Therapeutics is a pioneering TPD company dedicated to developing targeted protein degraders for human diseases with unmet medical needs. Founded by seasoned drug developers with deep knowledge and expertise in TPD drug discovery, the company has established a proprietary TPD discovery platform and robust screening capability. GluBio is advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas including oncology and immunology. The company has research operations in both San Diego, CA, USA and Shanghai, China.

Joes is innovating new ways to produce real meat, without the need to breed, feed and slaughter animals but by feeding cells. Our company has the first cultured meat platform for production and research in China. In December 2020, our company raised a 20 million yuan in financing from #Matrix Partners China for the research and industrialization of cultured meat technology.

Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.

XellSmart is a biotechnology company dedicated to developing scalable, low-cost, allogeneic stem cell therapies derived from induced pluripotent stem cells (iPSCs) to treat major degenerative diseases with high unmet medical need—such as ALS and Parkinson’s disease. With in-house GMP manufacturing, a state-of-the-art R&D center, and FDA-recognized clinical programs, we are transforming cutting-edge science into accessible, off-the-shelf regenerative solutions. This page is dedicated to sharing our journey, achievements, and breakthroughs as we work to reshape the future of neurological care.

Founded in 2017, Pluslife is best known for its Palm-Sized Mini Dock Molecular POC System. The technology behind called RHAM, a self-invented and patented nucleic acid isothermal amplification detection technology that is comparable to lab PCR test performances. Driven by RHAM, more products were launched to the market, which included Dock Pro 8 Molecular POC System, HPV 16/18/46 Test, STD CT/NG/UU Test, COVID-19/Flu A/Flu B Test, etc.

Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston.

Sanegene Bio is a clinical-stage, fully integrated biotechnology company backed by a syndicate of private equity investors. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is headquartered in Boston, with R&D operations in both the U.S. and China. Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.

Bioyond Robotics specializes in intelligent automation, tailored specifically for the life sciences industry. Headquartered in Dublin, with subsidiaries in Boston, Munich, London, and Shanghai. Bioyond boasts a founding team hailing from the world’s top 500 companies in robotics and life sciences, blending profound scientific research acumen with extensive product development prowess. Leveraging cutting-edge robotics, vision, and artificial intelligence technologies, we provide more user-friendly and efficient products and solutions for laboratories across scientific research, clinical diagnostics, and analytical. Our ambition is to empower scientists to drive global healthcare breakthroughs by liberating them from repetitive tasks, allowing them to focus on discovery and innovation. Together, we can unlock new possibilities and bring unparalleled value to humankind.

Founded in 2018, Hope Medicine Inc is a first-in-class innovative drug research and development company with a global vision and a focus on improving the quality of human life.

EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.

Aulis Capital is a global investment firm focusing on the health care industry. We partner with early and growth stage companies, leveraging scientific, analytical and investment expertise to accelerate innovations that improve patient care and advance medical technology. Contact: info@auliscapital.com

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Emulate Inc. is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready Human Emulation System® includes three components: Zoë® Culture Module, Organ-Chips, and analytical software applications. The platform provides a window into the inner workings of human biology and disease—offering researchers a new technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection and have also been awarded Product Design of the Year 2015 by London’s Design Museum.

ChemLex is a Singapore-based company delivering autonomous chemical synthesis services for the pharmaceutical and biotech industry. Our AI-integrated autonomous synthesis platform improves quality, consistency, and productivity while reducing costs and supporting ESG goals.